Nama's AI scorecard currently rates Mirum Pharmaceuticals Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does MIRM report earnings?

Mirum Pharmaceuticals's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$0.44.

What is the MIRM price target?

The median analyst price target from 14 analysts is $153.00, with a range of $118.00 – $200.00.

Is MIRM Shariah compliant?

Nama's AAOIFI-style screen reads Mirum Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Mirum Pharmaceuticals (MIRM)

Healthcare · Biotechnology · NASDAQ

Mirum Pharmaceuticals (MIRM) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $6.12B and a free-cash-flow yield of 1.2%. Over the most recent reported fiscal year, revenue grew 54.7%. Nama's AI scorecard rates it Sell, 2.8 out of 10. On 12-month momentum it ranks in the middle band of its market.

AI scorecard

Sell · 2.8/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Middle · +19.1% over 12 months ex. last

Middle fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-27.9%

How far the last close sits under the highest price of the past five years.

Market cap	$6.12B
Trailing P/E	—
Price / book	—
Price / sales	9.8
FCF yield	1.2%
Dividend yield	—
Gross margin	81.7%
Operating margin	-14.8%
Net margin	-139.2%
Revenue growth (YoY)	+54.7%
Revenue growth (3-yr annual)	+89.1%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.6
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

MIRM earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate -$0.44). Beat the EPS estimate in 0 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	-$0.42	-$0.41	-2.4%	$185.72M
Q2 2026	Aug 5, 2026	-$0.80	-$0.75	-6.7%	$176.24M
Q1 2026	May 6, 2026	-$1.08	-$0.35	-208.6%	$159.88M
Q4 2025	Feb 25, 2026	-$0.12	$0.06	-300.0%	$148.93M

MIRM analyst price target

Median target $153.00 from 14 analysts, ranging $118.00 – $200.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live MIRM data on Nama Insights →

MIRM FAQ

Is MIRM a buy?: Nama's AI scorecard currently rates Mirum Pharmaceuticals Sell (2.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does MIRM report earnings?: Mirum Pharmaceuticals's next scheduled report is on Feb 24, 2027. Analysts expect EPS of -$0.44.
What is the MIRM price target?: The median analyst price target from 14 analysts is $153.00, with a range of $118.00 – $200.00.
Is MIRM Shariah compliant?: Nama's AAOIFI-style screen reads Mirum Pharmaceuticals as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.